Kangmei Pharmaceutical(600518.SH) announced on November 11th, 2024, that the company's stocks continued to hit the limit up, with a significant short-term increase in stock price. In the first three quarters of 2024, the company achieved revenue of 3873.5583 million yuan, with a net income attributable to shareholders of the listed company of 5.0155 million yuan, and a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of -179.5222 million yuan. The company's current production and operation activities are normal, the basic fundamentals have not undergone significant changes, and the profitability still needs further recovery.

The board of directors of the company confirmed that, apart from the matters already publicly disclosed, as of now, the company and its controlling shareholders do not have any significant information that should be disclosed but has not been disclosed by the company.